A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
Last Updated August 28, 2024
Want to learn how to participate in this trial?
CR109330
OVERVIEW
-
Sexes Eligible for Study
male -
Age
years -
Phase
phase 11 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.
CONDITIONS
- Advanced Prostate Cancer
ELIGIBILITY
Inclusion Criteria:
* Metastatic castration-resistant prostate cancer (mCRPC) as defined by Prostate Cancer Working Group 3 (PCWG3): Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted. However, small c
DETAILS
LOCATIONS
| Country (2) | City or Province (5) | Status |
| United States | Aurora University of Colorado Anschutz Medical Campus |
RECRUITING
|
| United States | New York Herbert Irving Comprehensive Cancer Center Columbia University Medical Center |
RECRUITING
|
| United States | San Antonio South Texas Accelerated Research Therapeutics, LLC (START) |
RECRUITING
|
| France | Lyon Centre Leon Berard |
RECRUITING
|
| France | Villejuif Institut Gustave Roussy |
RECRUITING
|
39.72943, -104.83192
40.71427, -74.00597
29.42412, -98.49363
45.74848, 4.84669
48.7939, 2.35992
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.